Navigation Links
Study Rates Heart Health of Popular Diet Plans
Date:10/5/2007

Ornish beat Atkins, but any weight loss is good for the heart, researchers say

FRIDAY, Oct. 5 (HealthDay News) -- Not all diet plans are equally heart-healthy, according to a study ranking eight popular weight-loss programs.

Diets that emphasize a variety of fruits and vegetables scored better than those with a heavy protein focus.

The Ornish diet plan came out on top with the most potential to prevent heart disease risk factors. The Atkins diet came in last, lagging behind the Zone and Weight Watchers.

"It was not surprising to me that the Ornish diet came out on top given that the index used is designed to measure dietary components related to risk of heart disease," said dietician Lona Sandon, a national spokeswoman for the American Dietetic Association.

Sandon said the take-home message for consumers is "if heart disease is your concern, you need to focus more on fruits, vegetables and make all your grains whole grains, as well as limit intake of animal foods and fats."

The findings are published in the October issue of the Journal of the American Dietetic Association.

Researchers at the University of Massachusetts Medical School ranked daily meal plans and food recommendations in the Ornish Plan, the Zone Diet, Atkins, two Weight Watchers plans, the South Beach Diet, the New Glucose Revolution and the 2005 MyPyramid plan.

The rankings were based on the Alternate Healthy Eating Index (AHEI), which uses the daily dietary intake of fruits, vegetables, fats, fiber, nuts, soy and white meats instead of red meat to determine how much benefit a diet has for heart health.

The highest possible score is 70. While none of the diets had a perfect score, they varied across a 20-point spread:

  • Ornish, 64.6.
  • Weight Watchers high-carbohydrate, 57.4.
  • New Glucose Revolution, 57.2.
  • South Beach Phase 2, 50.7.

  • '/>"/>

Copyright©2007 ScoutNews,LLC.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Rural Canadians travel far for specialists: study
2. A new study surpasses Gene Therapy Hurdle
3. Tomato Sauce reduces Cancer Risk- Study
4. A question on study of Adult Stem Cell
5. Study on obesity and heart failure
6. National Lung Study in the process
7. Marijuana gateway theory strengthened by study of twins
8. Old theory of adaptation confirmed by new study
9. Study casts doubt on keyboard ills
10. Gene study links endometriosis, infertility
11. Study reveals how stress can make you sick
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2008)...-five day OnBase deployment critical in electronic...efit patients, CLEVELAND, July 9 /PRNewswire/ -- ...rise document management software suite, announced...sults since the deployment of,OnBase in March. Bas... four,states, SSM is a forward-thinking health car...
(Date:7/9/2008)...NTO, July 9 /PRNewswire-FirstCall/ - MDS Inc. (TSX...and services to the global life,sciences markets, ...f,Canada Limited (AECL) with notice of arbitration...el AECL to fulfill its contractual obligations,und... (ILTSA) and if not,granted, seeking significant m...
(Date:7/9/2008)... DRE, Inc., a premier internation...s its customers that as much as $250,000 in medica...come tax filings. , Louis...mulus Act of 2008, in accordance with Tax Code Sec...al equipment bought in 2008. This could make 2008 ...
(Date:7/9/2008)... InsuranceSpecialists.com, a lead...or almost a decade, now offers comprehensive infor...idential candidates are taking on health reform as...ment-free, supplies unbiased material on medical, ...elp consumers make the best choices in coverage fo...
Breaking Medicine News(10 mins):Health News:SSM Health Care Upgrades Patient Care With Speedy Document Management Implementation 2Health News:SSM Health Care Upgrades Patient Care With Speedy Document Management Implementation 3Health News:MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada 2Health News:MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada 3Health News:Economic Stimulus Act Can Improve Medical Equipment Purchasing Power 2Health News:InsuranceSpecialists.com Looks at the Candidates and Health Reform 2Health News:InsuranceSpecialists.com Looks at the Candidates and Health Reform 3
...cay has been developed by BASF, a German company, ...The company claims its// product can reduce the am... The product was developed in collaboration with ... The gum helps in fighting tooth decay by prevent...
...s and soft drinks in hospitals, schools and other ...betes and obesity. Australia// has the world's fa...is strongly linked with type-2 diabetes. In an ar... Journal of Australia, Paul Zimmet, Director of th...
...eens' attitudes that covers an overall picture of ...immoral practices, one// third of the American tee...gal drugs were used while their parents were at ho...e aware of what was happening when teenagers parti...
... breast cancer test, which could save several wome...ady, doctors have been using core needle biopsy to...ination. This new test involves the study of gen...s may help in detecting more aggressive cancers th...
Other Medicine News:Health News:Parents ignorant about kids' immoral practices 2Health News:Novel test for diagnosis of breast cancer 2
(Date:7/6/2008)...rketing Authorization Application currently ...E, July 7 /- Cell Therapeut...ced the publication of results from its,randomized...poliglumex,CT-2103) with gemcitabine or vinorelbi...) patients with previously untreated non-small cel...
(Date:7/3/2008)...ewswire-USNewswire/ -- All newborn infants,should ...esent at birth,according to a new recommendation ...recommendation and the accompanying summary of evi...Children whose hearing is impaired at birth, durin...with verbal and nonverbal communication and,social...
(Date:7/3/2008)...MBRIDGE Massachusetts, July 3,/PRNewswire-FirstCal...ology company, Jerini AG for an equity purchase p...a (HAE) product, FIRAZYR(R), to its Human Genetic... global sales expected to be around $350-400 mill...ve environment, - Expected to be accretive for No...
(Date:7/2/2008)...y Endpoint Met in Stage 1 of Two-Stage Study ...ble Patients to Date Continue to Show Objective Tu...e -, TUSTIN, Calif., July 2 /PRNewswire-FirstCall...M ) today reported that its lead product,candidate...imary endpoint,in its ongoing Phase II clinical tr...
Breaking Medicine Technology:Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5Task Force Recommends Screening for Hearing Loss in All Newborns 2Task Force Recommends Screening for Hearing Loss in All Newborns 3Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 2Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 3Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 4Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 5Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 6Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 7Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 8Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer 2Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer 3Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer 4CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 139 1CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 139 2CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 139 3International study strengthens case for daily calcium pill 195 1International study strengthens case for daily calcium pill 195 2Methamphetamine study suggests increased risk for HIV transmission 192 1Methamphetamine study suggests increased risk for HIV transmission 192 2Embryonic Stem Cells Repair Human Heart 190 1Embryonic Stem Cells Repair Human Heart 190 2Embryonic Stem Cells Repair Human Heart 190 3
...Presented at Society of Nuclear,Medicine Annual Me...stCall/ --,Immunomedics, Inc. , a biopharmaceutica...ies to treat cancer and other serious,diseases, to...en,(CEA) antibody, labetuzumab, labeled with the r...active when given in two doses,to patients with co...
...omide in Multiple Myeloma,Presented at the America..., CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ --...ults of a Phase III study,demonstrating that the a...s overall survival (OS) by 17.6 months in patients...eloma compared to the,current standard of care. Th...
Other Medicine Technology:Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 2Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 3Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 4Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 5Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 2Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 3Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 4Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 5Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 6
The ProtecPoint Exit Alerting System, instantly help protect individuals (e.g. patients, staff) and assets (e.g. medical equipment), with easily-mountable exit controllers placed throughout your faci
...nt of controlled substances, critical supplies, or...vess" are designed to perform this function. Conti...ervention. Radio frequency identification (RFID) t...lf™ product solutions incorporate custom desi...
Agility can facilitate bed and room management through business process optimization using RFID technology. Bed and room management may be integrated with other AgileTrac products.
Assetrac allows identification, location, and protection of your assets.
Medicine Products: